Intermittent levosimendan infusions in advanced heart failure: a real world experience. (February 2017)

• Record Type: Journal Article
• Authors: Ortis, Benedetta; Villani, Alessandra; Oldani, Matteo; Giglio, Alessia; Ciambellotti, Francesca; Facchini, Mario; Parati, Gianfranco; Malfatto, Gabriella
• Is Part Of: Journal of international medical research. Volume 45:Number 1(2017)
• Page Start: 361
• Page End: 371
• Publication Date: 2017-02
• Subjects: Advanced chronic heart failure -- intermittent levosimendan -- inotropic drugs; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060516655244
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: To analyse the effects of levosimendan infusions in advanced heart failure. Methods: Patients with advanced heart failure treated with repeated levosimendan infusions were retrospectively compared with controls. Clinical, blood and echocardiographic parameters were obtained at baseline and after 12 months, and before and after each levosimendan infusion. Hospitalizations for heart failure and in-hospital length of stay in the 6 months before enrolment and after 6 and 12 months were recorded, along with 1-year mortality. Results: Twenty-five patients treated with levosimendan and 25 controls were studied. After each levosimendan infusion, ventricular function and various clinical and metabolic parameters were improved. After 12 months, left ventricular ejection fraction (LVEF) had improved compared with baseline in the levosimendan group. The 1-year mortality rate was similar in both groups. During the 6 months before enrolment, hospitalizations were fewer in controls compared with the levosimendan group; after 6 and 12 months they increased in controls and decreased in the levosimendan group. Seven patients were super-responders to levosimendan, with LVEF improving more than 20% and hospitalizations being reduced at 12 months compared with the rest of the levosimendan group. Conclusion: Intermittent levosimendan improved LVEF and decreased hospitalizations in advanced heart failure and represents a therapeutic option for patients whose disease is worsening.